Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Regeneron Pharmaceuticals Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One increased by 5.5% to $5.79B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.1%, from $5.26B to $5.79B. Over 5 years (FY 2020 to FY 2025), Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One shows an upward trend with a 31.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Higher values indicate greater near-term liquidity from the investment portfolio, reducing reliance on external financing.
Detailed definition
This represents the portion of the available-for-sale debt securities portfolio that is scheduled to mature within the f...
Peer comparison
Consistent with standard treasury management practices for large-cap firms with significant cash reserves.
other_available_for_sale_securities_debt_maturities_with_de2040Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.84B | $2.36B | $2.81B | $3.70B | $4.17B | $3.53B | $4.64B | $5.04B | $7.00B | $7.79B | $8.11B | $7.92B | $7.89B | $7.78B | $6.52B | $5.26B | $5.47B | $5.94B | $5.49B | $5.79B |
| QoQ Change | — | +28.1% | +19.3% | +31.9% | +12.6% | -15.4% | +31.3% | +8.8% | +38.8% | +11.2% | +4.2% | -2.4% | -0.4% | -1.3% | -16.2% | -19.4% | +4.1% | +8.5% | -7.6% | +5.5% |
| YoY Change | — | — | — | — | +126.9% | +49.9% | +65.0% | +36.1% | +67.8% | +120.5% | +75.0% | +57.0% | +12.7% | -0.0% | -19.6% | -33.6% | -30.6% | -23.7% | -15.9% | +10.1% |
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one?
- Regeneron Pharmaceuticals (REGN) reported debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one of $5.79B in Q1 2026.
- How has Regeneron Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one changed year-over-year?
- Regeneron Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one increased by 10.1% year-over-year, from $5.26B to $5.79B.
- What is the long-term trend for Regeneron Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one has grown at a 31.5% compound annual growth rate (CAGR), from $1.39B to $5.49B.
- What does debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one mean?
- The value of debt investments maturing within the next twelve months.